Kezar Life Sciences (NASDAQ:KZR) Announces Quarterly Earnings Results, Misses Estimates By $0.60 EPS

Kezar Life Sciences (NASDAQ:KZR) issued its quarterly earnings results on Friday. The company reported ($1.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.60), FiscalAI reports.

Kezar Life Sciences Price Performance

Shares of Kezar Life Sciences stock traded down $0.15 during mid-day trading on Friday, reaching $6.20. 27,254 shares of the stock were exchanged, compared to its average volume of 37,189. Kezar Life Sciences has a fifty-two week low of $3.53 and a fifty-two week high of $7.45. The company has a market cap of $45.40 million, a price-to-earnings ratio of -0.73 and a beta of 0.53. The firm has a 50-day simple moving average of $6.52 and a 200 day simple moving average of $5.87. The company has a current ratio of 7.07, a quick ratio of 7.06 and a debt-to-equity ratio of 0.02.

Institutional Trading of Kezar Life Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Landscape Capital Management L.L.C. acquired a new stake in shares of Kezar Life Sciences in the third quarter valued at approximately $51,000. Torno Capital LLC acquired a new stake in shares of Kezar Life Sciences in the 4th quarter valued at $126,000. Woodline Partners LP bought a new stake in shares of Kezar Life Sciences during the first quarter worth $125,000. Dimensional Fund Advisors LP lifted its stake in shares of Kezar Life Sciences by 14.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company’s stock valued at $167,000 after acquiring an additional 3,312 shares during the period. Finally, State Street Corp boosted its holdings in Kezar Life Sciences by 28.4% in the fourth quarter. State Street Corp now owns 27,093 shares of the company’s stock valued at $170,000 after acquiring an additional 6,000 shares during the last quarter. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Kezar Life Sciences in a research report on Monday, December 22nd. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kezar Life Sciences presently has an average rating of “Reduce” and an average price target of $6.00.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.